Umoja Biopharma vs 80 Acres Farms

Side-by-side comparison of AI visibility scores, market position, and capabilities

Umoja Biopharma

EmergingBioTech

Cell Therapy

Umoja Biopharma raised $300M+ for its lentiviral vector CAR-T platform that delivers cancer-fighting T-cells in a single IV infusion, eliminating the need for cell extraction and manufacturing.

About

Umoja Biopharma is developing an in vivo CAR-T cell therapy platform that circumvents the costly and time-consuming ex vivo manufacturing process that limits current CAR-T therapies. Instead of extracting a patient's T-cells, engineering them in a lab, and reinfusing them, Umoja's approach delivers viral vectors intravenously that reprogram T-cells directly inside the patient's body. This could reduce CAR-T therapy costs from $400,000+ to a fraction of that price.

Full profile

80 Acres Farms

ChallengerAgTech

Indoor Vertical Farming

Raised $115M (Feb 2026) led by General Atlantic. Post-merger with Soli Organic creates largest indoor farm in North America. ~$200M combined first-year revenues.

About

80 Acres Farms is a commercial-scale indoor vertical farming company that, following its merger with Soli Organic, operates the largest indoor farming network in North America. The company raised $115 million in February 2026 led by General Atlantic, with projected first-year combined revenues approaching $200 million — making it one of the few vertical farming companies to achieve genuine commercial scale after years of industry attrition that eliminated several high-profile competitors.

Full profile

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.